

# HELICOBACTER PYLORI

## HELICOBACTER PYLORI

*H. pylori* is involved in the aetiology of a number of common gastroduodenal diseases, such as chronic gastritis, peptic ulceration and gastric cancer. Although Bizzozero identified the presence of spirochaetal organisms in gastric mucosa, it was not until the early 1980s that Warren and Marshall confirmed Koch's postulates with respect to *H. pylori* and gastritis. Both received the Nobel Prize in Medicine or Physiology in 2005. (b)

120 Liquid Solid 100 80 60 40 Proportion remaining 20 0 0 40 60 10 30 50 20 Time (min) Figure 67.8 Dual-phase solid and liquid gastric emptying. The use of two isotopic labels allows the liquid and solid phases of the emptying to be followed separately. (a) Image acquisition. (b) Gastric emptying curves in a normal individual showing a typical lag period in the solid phase before linear emptying (courtesy of Dr V Lewington, Southampton, UK).

lyse urea, resulting in the production of ammonia, a strong alkali. The effect of ammonia on the antral G cells is to cause release of gastrin via a negative feedback that is responsible for the modest, but inappropriate, hypergastrinaemia in patients with peptic ulcer disease, which, in turn, may result in gastric acid hypersecretion. The organism's obligate urease activity is utilised by various tests used to detect the presence of the organism, including the C and C breath tests and the CLO test (a commercially available urease test kit), which is performed on gastric biopsies. The organism can also be detected histologically (Figure 67.9), using the Giemsa or the Ethin-Starry silver stains, and cultured using appropriate media. Previous or current infection with the organism may also be detected serologically. Breath tests or faecal antigen tests are recommended for the pretreatment diagnosis of *H. pylori* infection in the community. Less accurate, hospital-based serology tests have a place within a non-invasive test-and-treat strategy. Infection with *H. pylori* leads to disruption of the gastric mucous barrier by the enzymes produced by the organism, and the inflammation induced in the gastric epithelium is the basis of many of the associated disease processes. The association of the organism with chronic (type B) gastritis is not in doubt. Some strains of *H. pylori* produce cytotoxins, notably the Cag A and Vac A products. Production of cytotoxins seems to be associated with the ability to cause gastritis, peptic ulceration and gastric cancer. The effect of the organism on the gastric epithelium is to incite a classical inflammatory response that involves the migration and degranulation of acute inflammatory cells, such as neutrophils, and also the accumulation of chronic inflammatory cells, such as macrophages and lymphocytes. It is evident how *H. pylori* infection results in chronic gastritis and also how this may progress to gastric ulceration, but for a while it remained unclear how the organism could be involved in duodenal ulceration, as the normal duodenum is not colonised. As mentioned above, the production of ammonia does increase the level of circulating gastrin and it has been shown subsequently that eradication of the organism in patients with duodenal ulcer disease will reduce the acid levels to normal subjects and those with duodenal ulcers is considerable and the modestly increased acid levels in patients with *Helicobacter*-associated antral gastritis are insufficient to

explain the aetiology of duodenal ulceration. The explanation can probably be found in the phenomenon of duodenal gastric metaplasia. Gastric metaplasia is the normal response of the duodenal mucosa to excess acidity. It can be thought of in the same way as any other metaplasia in the gastrointestinal tract: an attempt by the mucosa to resist an injurious stimulus. Although normal duodenal mucosa cannot be infected with *H. pylori*, gastric metaplasia in the duodenum is commonly infected and this infection results in the same inflammatory process that is observed in the gastric mucosa. The result is duodenitis, which is almost certainly the precursor of duodenal ulceration. Infection with *H. pylori* may be the most common human infection. The incidence of infection within a population increases with age, and in many populations infection rates of 80–90% are not unusual. Up to 50% of the world's population may be infected with *Helicobacter*. It appears that most infection is acquired in childhood and the possibility of infection is inversely related to socioeconomic group. The means of spread has not been identified, but the organism can occur in the faeces and faecal–oral spread seems most likely. The organism is not normally found in saliva or dental plaque. There is evidence in different environments and in different population groups that the manifestations of the infection may be different. Predominantly antral gastritis, which is commonly seen in the West, results initially in increased levels of acid production and peptic ulcer disease, whereas gastritis affecting the body, common in the developing world, may lead to hypochlorhydria and gastric neoplasia. It has been known since 1984 that *Helicobacter* infection is amenable to treatment with antibiotics. The profound hypochlorhydria produced by PPIs combined with antibiotics is also effective in eradicating the organism. Commonly used eradication regimes include a PPI and two antibiotics, such as metronidazole and amoxicillin. Very high eradication rates, mainly in the region of 90%, can be achieved with combinations that include the antibiotic clarithromycin, although it may be that in the future antibiotic resistance will become a problem. Reinfection following successful eradication appears rare (<0.5%) but incomplete eradication is a more important clinical problem. At present, eradication therapy is recommended for patients with duodenal ulcer disease, but not for patients with non-ulcer dyspepsia or in asymptomatic patients who are infected. However, recent data show that a proportion of patients with non-ulcer dyspepsia do respond to treatment. *H. pylori* is now classified by the World Health Organization as a class 1 carcinogen, and it may be that the further epidemiological studies on the risk of gastric cancer change current advice on treatment.

Figure 67.9 Antral mucosa showing colonisation with *Helicobacter pylori* (modified Giemsa stain).

---

Revision #1

Created 2025-12-31 15:24:59 UTC by Omar Ayman

Updated 2025-12-31 15:24:59 UTC by Omar Ayman